Association between KRAS mutation and alcohol consumption in Brazilian patients with colorectal cancer Authors: Bianca Gomes-Fernandes, Luísa Martins Trindade, Marcela de Castro Bastos Rodrigues, João Pedro Duarte Cardoso, Frederico Temponi Lima, Luíza Rogerio, Simone de Vasconcelos Generoso, Juliana Garcia Carneiro, Rodrigo Gomes da Silva, Renan Pedra de Souza, Luiz De Marco, Luciana Bastos-Rodrigues Published: 2024 ABSTRACT Colorectal cancer (CRC) is a leading cause of morbidity and mortality worldwide. Detection before metastasis and efficient treatment of disease significantly improve patient survival and quality of life. However, limitations in diagnosis and postoperative surveillance are associated with low CRC detection and survival rates. Thus, this project aimed to evaluate the molecular profile of patients diagnosed with CRC, as molecular biomarkers constitute a new frontier for diagnosis, treatment and prognosis. Methods and Results: 42 patients were included in the study, predominantly male (59.5%), with a median age of 63 years (SD: 10.0; min: 41; max: 83). The majority of primary tumors were located in the rectum (38.1%), in the sigmoid (33.3%) and in the ascending (21.4%) colon. We evaluated the genes KRAS, NRAS, BRAF, EGFR and TP53 using Sanger sequencing. Somatic and germline mutations were found in the KRAS, EGFR and TP53 genes, with the most common somatic alteration being rs121913529 in KRAS. This variant was also strongly associated with alcoholism (p = 0.002). Furthermore, patients with somatic mutations in TP53 had significantly higher mortality compared to those with wild-type alleles (OR: 11.2; 95% CI 1.25–2.45). Conclusions: Our findings support a relationship between alcohol consumption and the rs121913529 mutation, which is classified as pathogenic for colorectal cancer. Thus, further studies investigating the link between alcohol consumption, colorectal carcinogenesis and tumor progression ought to be conducted.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-024-75048-2. Introduction Colorectal cancer (CRC) is an important cause of morbidity and mortality worldwide1–3, and the second non-skin malignancy with the highest incidence rates in both male and female Brazilians4. Genetic and behavioural patterns contribute to this scenario. Among the latter, alcohol consumption, an increasingly common practice in Western cultures, is recognized as one of the main risk factors for CRC5. Indeed, moderate to heavy alcohol use has been shown to be an independent risk factor in the early stages of the adenoma-carcinoma sequence6, but despite this evidence, the precise attributable risk related to CRC and alcohol consumption is inconclusive, as some reports have shown no excess risk5–12. Tumor development or carcinogenesis is driven by several biochemical disruptions, such as epithelial barrier dysfunction, microbiotic changes, decreased uptake or increased breakdown of folate, effects of dietary nitrosamines and epigenetic modulation5,13. These changes facilitate somatic mutations and, as mutated cells multiply, decreased DNA repair and dysregulated mitosis drive further mutation, affecting intracellular signalling pathways such as the WNT, MAPK, PI3K, TGFβ and P53 pathways14 and leading to neoplastic development and progression. Tumors arise from either the classic route, initiated by tubular adenomas, and the alternative, which arises from serrated polyps15. Some genes affect both pathways, such as KRAS. Others have only been observed to be altered in one of them, such as BRAF, which has been implicated only in the alternative pathway. Understanding the molecular patterns of CRC is essential for comprehension of genotype-phenotype correlations intrinsic to disease processes. The identification of biomarkers associated with CRC allows development of innovative and personalised intervention strategies, from population-wide screening to post-treatment monitoring16. In this study, we evaluated the proto-oncogenes KRAS, NRAS, BRAF and the tumor suppressor gene TP53, as well as the EGFR gene, which is also closely related to CRC development. Furthermore, we evaluated the association between variants detected in these genes and alcohol consumption and mortality in individuals with CRC. Materials and methods Study population This cross-sectional study recruited 42 Brazilian adults with CRC, admitted to Hospital das Clínicas da UFMG from December 2019 to December 2021. Patients between 18 and 85 years diagnosed with CRC and scheduled for surgical resection were included in the study. All subjects voluntarily participated and signed an informed consent form prior to inclusion. The project was approved by the institutional Research Ethics Committee, under CAAE #28579819.6.0000.5149. The study has been performed in accordance with the Declaration of Helsinki. Alcohol consumption Patients who stated alcohol use were inquired about beverage type (beer, wine or spirits) and amount (in cans, bottles, glasses or doses) of daily consumption. Daily alcohol ingestion was calculated using estimates from Centro de Informações sobre Saúde e Álcool - CISA (2023), in which a single standard dose - a bottle or a can of beer (350 mL), a glass of wine (150 mL) or a dose of distilled liquor (45 mL) - represents 14 g of ethanol17,18. Cutoffs were 12.5 g/day or less for mild consumption, 12.5 to 50 g/day for moderate consumption and over 50 g/day for high consumption19. Studied samples The surgical team collected fragments of tumor (TT) and normal (NT) tissue during resection. Normal colonic tissue was extracted at least 5 cm away from the primary lesion. Samples were placed in sterile 1.5 mL micro tubes filled with 1.0 mL of RNAlater® solution immediately after the surgical procedure and stored in a freezer at -80 °C. DNA isolation and Sanger sequencing Cell DNA was isolated from TT and NT fragments using a Protein-K based protocol20. Exons 2–3 of KRAS and NRAS, exons 18–21 of EGFR and exons 4–9 of TP53 were amplified by PCR using Platinum™ Taq DNA Polymerase (Thermo Fisher Scientific, USA). Region-specific primers were designed with Primer3 v.4.0 9 (sequences available upon request). PCR products were analysed and purified using Wizard® SV Gel and PCR Clean-Up System (Promega). Bidirectional DNA sequencing was performed using BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems) and ABI 3130 DNA analyzer (Applied Biosystems). The chromatograms were manually inspected in Sequencher v. 4.1.4. Statistical analysis All analyses were performed using R software, version 3.5.1. The Mann-Whitney test was used to compare dichotomous variables with numeric variables, while we opted for the Kruskal-Wallis test for categorical variables with more than two groups. The chi-squared test was employed for comparisons between categorical variables. We estimated odds ratios (OR) and 95% confidence intervals (CI) adjusted for smoking, alcohol consumption, exercise frequency and dietary habits for various genotypes and haplotypes using logistic regression analysis, with a statistical significance threshold of P = 0.05. Results In total, 42 CRC patients were included in the study. 84 tissue samples were collected, of which 42 were tumor tissue and 42 were normal tissue. Most patients were male (59.5%), with a median age of 63 years (SD: 10.0; min: 41; max: 83). Primary tumors were located in different parts of the colon, more frequently in the rectum (38.1%). Three patients (7.1%) were diagnosed in stage I, 20 (47.6%) in stage II, 14 (33.3%) in stage III and four (9.5%) were diagnosed with metastatic CRC at baseline. More details on the clinical profile in Table 1. Table 1Clinical profile patients.VariablesColonRectumTotalRightTransverseLeft*SigmoidAgeAverage675652636363Median685652656163GenderMasculine50181125Feminine4116517EthnicityWhite2005512Black111047Brown6019723StadiumI000213II6017620III2005714IV110024TNMT1000000T2000224T37019926T42103511N06019824N+3105817M0/Mx801141437M1110024Caption: Profile of patients in relation to average and median age, and number of patients of each gender, self-reported ethnicity and staging.*Of the patients with a tumor in the left colon, one did not have the staging available. Table 1Clinical profile patients.VariablesColonRectumTotalRightTransverseLeft*SigmoidAgeAverage675652636363Median685652656163GenderMasculine50181125Feminine4116517EthnicityWhite2005512Black111047Brown6019723StadiumI000213II6017620III2005714IV110024TNMT1000000T2000224T37019926T42103511N06019824N+3105817M0/Mx801141437M1110024Caption: Profile of patients in relation to average and median age, and number of patients of each gender, self-reported ethnicity and staging.*Of the patients with a tumor in the left colon, one did not have the staging available. Clinical profile patients. Caption: Profile of patients in relation to average and median age, and number of patients of each gender, self-reported ethnicity and staging. *Of the patients with a tumor in the left colon, one did not have the staging available. Regarding personal and family history, 35 patients had at least one comorbidity (83.3%). The most reported conditions were hypertension (64.2%), diabetes mellitus (19.0%) and obesity (9.0%). 23 participants (54.8%) reported family history of cancer and nine (21.4%) specifically mentioned a family history of CRC. Patients were followed for 23 months. By the last follow-up assessment, four patients (9.5%) had died. Regarding alcohol and tobacco use, six patients (14.3%) were smokers, 12 (28.6%) were former smokers, 11 (26.2%) were alcohol users and nine (21.4%) were former smokers and alcohol users. Somatic mutations were found in KRAS and TP53 (Table 2). The most frequent mutated variant was rs121913529 (KRAS), present in 11 (26.2%) tumor samples. This alteration was positively correlated with alcohol use (p = 0.002). On average, patients consumed 15.14 g/day of ethanol. Only one patient (14.3% of the total reported) ingested over 30 g/day, the maximum dose stipulated by the World Health Organization (WHO), with consumption of 36 g/day. Another four patients consumed the equivalent of 2 g/day, 10 g/day, 20 g/day and 28 g/day and, finally, two patients ingested approximately 4 to 6 g/day of alcohol. Table 2Somatic changes identified.GeneVariantSpecificationsFAFRMAFABraOM KRAS rs121913529 Exonic; Missense819,1%< 1%NRc.35G > T; p.Gly12Val24,8%c.35G > C; p.Gly12Ala12,4%c.35G > A; p.Gly12Asp511,9% rs112445441 Exonic; Missensec.38G > A; p.Gly13Asp37,1%< 1%NR TP53 rs28934578 Exonic; Missensec.524G > A; p.Arg175His37,1%< 1%NR rs28934575 Exonic; Missensec.733G > A; p.Gly245Ser12,4%< 1%NR rs121912651 Exonic; Missensec.742 C > T p.Arg248Trp37,1%< 1%NR rs11540652 Exonic; Missensec.743G > A; p.Arg248Gln12,4%< 1%NR rs1064794311 Exonic; Missensec.749 C > T; p.Pro250Leu12,4%< 1%NR rs121913343 Exonic; Missensec.817 C > T; p.Arg273Cys12,4%< 1%NR rs28934576 Exonic; Missensec.818G > A; p.Arg273His12,4%< 1% (T)NRCaption: Somatic alterations and their location in the gene, variant, specifications and frequency analysis. MAF: lowest allele frequency. FA: Absolute Frequency. FR: Relative Frequency. NR: Not Reported. Table 2Somatic changes identified.GeneVariantSpecificationsFAFRMAFABraOM KRAS rs121913529 Exonic; Missense819,1%< 1%NRc.35G > T; p.Gly12Val24,8%c.35G > C; p.Gly12Ala12,4%c.35G > A; p.Gly12Asp511,9% rs112445441 Exonic; Missensec.38G > A; p.Gly13Asp37,1%< 1%NR TP53 rs28934578 Exonic; Missensec.524G > A; p.Arg175His37,1%< 1%NR rs28934575 Exonic; Missensec.733G > A; p.Gly245Ser12,4%< 1%NR rs121912651 Exonic; Missensec.742 C > T p.Arg248Trp37,1%< 1%NR rs11540652 Exonic; Missensec.743G > A; p.Arg248Gln12,4%< 1%NR rs1064794311 Exonic; Missensec.749 C > T; p.Pro250Leu12,4%< 1%NR rs121913343 Exonic; Missensec.817 C > T; p.Arg273Cys12,4%< 1%NR rs28934576 Exonic; Missensec.818G > A; p.Arg273His12,4%< 1% (T)NRCaption: Somatic alterations and their location in the gene, variant, specifications and frequency analysis. MAF: lowest allele frequency. FA: Absolute Frequency. FR: Relative Frequency. NR: Not Reported. Somatic changes identified. Exonic; Missense c.38G > A; p.Gly13Asp Exonic; Missense c.524G > A; p.Arg175His Exonic; Missense c.733G > A; p.Gly245Ser Exonic; Missense c.742 C > T p.Arg248Trp Exonic; Missense c.743G > A; p.Arg248Gln Exonic; Missense c.749 C > T; p.Pro250Leu Exonic; Missense c.817 C > T; p.Arg273Cys Exonic; Missense c.818G > A; p.Arg273His Caption: Somatic alterations and their location in the gene, variant, specifications and frequency analysis. MAF: lowest allele frequency. FA: Absolute Frequency. FR: Relative Frequency. NR: Not Reported. Patients with TP53 mutations were more likely to die compared to those with wild-type alleles (OR 11.2; 95% CI 1.25–245). Germline changes were observed in EGFR and TP53 (Table 3). No changes were detected in the NRAS and BRAF genes. Table 3Germinal changes identified.GeneVariantSpecificationsFAFRMAFABraOM EGFR rs17337107 Intronic12,4%2% (A)3% rs17337135 Intronic49,5%1% (A)3% rs2017000 Intronic2047,6%33% (G)26% rs17290378 Intronic511,9%4% (C)6% rs555226828 Intronic12,4%< 1% (A)NR rs17290385 Intronic12,4%1% (A)1% rs712831 Intronic3890,5%33% (T)78% rs10241451 Intronic2324,8%17% (C)22% rs1050171 Exonic; Synonymousc.2361G > A; p.Gln787=3071,4%43% (A)54% rs17290552 Intronic37,1%3% (G)3% rs6970262 Intronic3583,3%25% (A)65% TP53 rs1042522 Exonic; Missensec.215 C > G; p.Pro72Arg3685,7%46% (G)67% rs966675626 Intronic12,4%< 1%< 1%Caption: Somatic alterations and their location in the gene, alteration, specifications and frequency analysis. MAF: lowest allele frequency - reported by Ensembl. FA: Absolute Frequency. FR: Relative Frequency. NR: Not Reported. Table 3Germinal changes identified.GeneVariantSpecificationsFAFRMAFABraOM EGFR rs17337107 Intronic12,4%2% (A)3% rs17337135 Intronic49,5%1% (A)3% rs2017000 Intronic2047,6%33% (G)26% rs17290378 Intronic511,9%4% (C)6% rs555226828 Intronic12,4%< 1% (A)NR rs17290385 Intronic12,4%1% (A)1% rs712831 Intronic3890,5%33% (T)78% rs10241451 Intronic2324,8%17% (C)22% rs1050171 Exonic; Synonymousc.2361G > A; p.Gln787=3071,4%43% (A)54% rs17290552 Intronic37,1%3% (G)3% rs6970262 Intronic3583,3%25% (A)65% TP53 rs1042522 Exonic; Missensec.215 C > G; p.Pro72Arg3685,7%46% (G)67% rs966675626 Intronic12,4%< 1%< 1%Caption: Somatic alterations and their location in the gene, alteration, specifications and frequency analysis. MAF: lowest allele frequency - reported by Ensembl. FA: Absolute Frequency. FR: Relative Frequency. NR: Not Reported. Germinal changes identified. Exonic; Synonymous c.2361G > A; p.Gln787= Exonic; Missense c.215 C > G; p.Pro72Arg Caption: Somatic alterations and their location in the gene, alteration, specifications and frequency analysis. MAF: lowest allele frequency - reported by Ensembl. FA: Absolute Frequency. FR: Relative Frequency. NR: Not Reported. Discussion Colorectal tumors arise as a result of mutational activation of oncogenes (altered proto-oncogenes) with mutational inactivation of tumor suppressor genes21. In our study, we evaluated the KRAS, NRAS, BRAF proto-oncogenes and the TP53 tumor suppressor gene. Associated with the aforementioned proto-oncogene pathway and the CRC carcinogenesis process is the EGFR gene, which was also evaluated in our study. KRAS-activating oncogenic mutations generally confer a worse prognosis and are often seen at residue positions 12, 13, and 61 in cancer patients22. According to Vatansever, Erman and Gümüş (2019), among these, G12 is the most frequently mutated residue (89%) and, more recurrently, mutates to aspartate (G12D, 36%) followed by valine (G12V, 23%) and cysteine (G12C, 14%)23. This ordering was observed in our study regarding the G12D and G12V alteration. Replacement with aspartate was the most frequent (11.9%), followed by valine (4.8%) and alanine (2.4%). Exchange for cysteine was not observed in our analysis. Our results demonstrate a significant association between ethanol consumption and SNP rs121913529. This variant, located in codon 12 of KRAS, in addition to being the most frequent somatic mutation (19.1%), was also associated with alcohol use regardless of dose (p = 0.002). Our data is consistent with the work of Sinha et al. (2013)16, which reported that alcohol intake was significantly associated with the presence of mutation in codon 12 of KRAS in Indian patients with CRC. Song et al. (2018) described that rs6687758 has been shown to interact with alcohol consumption in the etiologic of colorectal cancer19. In fact, alcohol intake, an increasingly common habit in contemporary society, is a major risk factor for CRC5. In a case-control study by Seol et al. (2021), alcohol intake increased the risk of CRC in East Asian populations11. Another study by Lee et al. (2019)10 found that the amount of alcohol consumption is positively correlated with risk of colorectal cancer, especially in women. Semmler et al. (2021) identified a linear relationship between alcohol consumption and risk of colorectal adenoma6. Thus, even low to moderate amounts of ethanol can contribute to colorectal neoplastic changes. Confounding variables include ethnicity, type of alcoholic beverage and associated habits such as smoking and low physical activity9. A study by Cerretelli et al. (2021) in a murine model of Lynch syndrome found that an ethanol-based treatment induces formation of zones of hyper proliferation in the colonic mucosal epithelium, acting as a tumor promoter12. Several mechanisms have been suggested to explain the effect of alcohol on CRC risk. It is widely believed that acetaldehyde, a metabolite of alcohol, is a carcinogen that disrupts DNA replication and repair13. Its accumulation can even suppress antioxidant defence systems and cause genetic alterations24. Dashti et al. (2017) described this metabolite in high concentrations in the colon after alcohol consumption and reinforced its carcinogenic role25. Chronic alcohol consumption disrupts folate metabolism, and folate deficiency is a risk factor for CRC26. This consumption can also change the epigenetic profile of the individual and favour the increase in the incidence of CRC24. Metabolic processes involving alcohol generate reactive oxygen species (ROS) that can damage proteins, lipids and DNA5,27. These DNA changes may explain the connection between alcoholism and the allelic variant at codon 12 of KRAS. In addition, colorectal neoplasia has been associated with altered non-neuronal acetylcholine (ACh) related protein metabolism. Acetylcholine-related proteins in non-neoplastic appearing colonic mucosa from patients with colorectal neoplasia28. One of these enzymes is Butyrylcholinesterase, that has been linked to infection risk and severity after colorectal surgery29. In our studies we have not looked at these enzymes. However, as alcohol promotes inflammation, the role of these biomarkers could also be related to CRC progression and deserves further studies. In addition to the somatic changes identified in KRAS, in our study, we observed that patients with a somatic mutation in TP53 are more likely to die than those who do not have a mutation in this tumor suppressor gene (OR 11.2; 95% CI 1, 25 − 2 ,45). Manoharan et al. (2020) describe that 95% of the pathogenic variants are found between exons 5 and 830. In our study, all pathogenic variants found in TP53 are between the referred exons (5–8), reflecting the cited percentage. Among all the exons analysed, exon 7 presented four somatic alterations (G245S, R248W, R248Q and P250L), with concordant in silico prediction, in the PolyPhen-2, SIFT and PROVEAN databases, for the existence of damages in the protein structure. Two pathogenic alterations (R273C and R273H) were identified in exon 8 of the TP53 gene. Between exon 8 and 9, the intronic rs966675626, however, without associated publications. In a study developed by Lin et al. (2021), R273C (rs121913343) was listed as a potential target for immunotherapy31. R273H (rs28934576), also a contact mutation32, has been shown to stimulate cancer cells to generate cancer stem cells33. Mutations in codon 273 have also demonstrated increased resistance to the drugs paclitaxel, cisplatin and doxorubicin34. In exon 5, a single variant was found, R175H (rs28934578), also pathogenic, identified in 7.1% of patients. This mutation has been associated with tumor growth and CRC metastasis35. In a study carried out by Humpton et al. (2018), tumors containing the R175H mutation were resistant to serine-limited conditions and less responsive to therapy, exhibiting worse outcomes36. Still in the therapeutic field, the R175H mutation has been listed as a promising target for cancer immunotherapies37. In a study carried out by Khromova and other participants (2009), the missense variants R175H, R248W, R273H, also found in the present study, showed an association with increased tumor vascularization by activation mediated by reactive oxygen species (ROS). The authors suggested that the combination of antiangiogenic drugs with antioxidants may increase the therapeutic efficacy of tumors that have P53 dysfunction38. Chiang and participants (2021) point out the functions of the alterations of R273H, R248W and R248Q as similar to those of R175H, highly dependent on the cellular context35. In addition to the KRAS and TP53 genes, alterations in the EGFR gene were also identified. This gene was highlighted in the scope of intronic alterations, with a total of 10 alterations identified (rs17337107, rs17337135, rs2017000, rs17290378, rs555226828, rs17290385, rs712831, rs10241451, rs17290552 and 20 rs62952). Among them, rs555226828 was the only one to present MAF below 1%, and its frequency was not reported in the Brazilian database (ABraOM). The rs17337135 and the rs17290385 had MAF of exactly 1%, and the remaining MAF greater than 1%, with a frequency described in the Brazilian bank. The most frequent intronic variant in our study was rs712831 (90.5%), followed by rs6970262 (83.3%). Although very frequent, the same was not observed for rs712831 in relation to the literature, as it was described in only one publication, made by Edvardsen and others involved (2013). These researchers identified rs712831 as associated with mRNA expression of 14 genes previously linked to fibrosis39. The rs6970262 was associated with Alzheimer’s disease40 and the risk of head and neck squamous cell carcinoma - HNSCC41. However, no studies were found addressing this genetic variation and CCR. Regarding exonic alterations in EGFR, rs1050171 (Q787 = or Q787Q) was identified in 30 (71.4%) cases. This synonymous polymorphism was shown to be associated with improved overall survival in patients with CRC in a study developed by Leichsenring et al. (2016)42. What is interconnected with the findings by Giordano et al. (2019), who presented rs1050171 as a potential predictive polymorphism of the effectiveness of anti-EGFR antibodies in CRC43. In addition, Bonin and company (2016) observed that patients with this polymorphism have better clinical evolution after anti-EGFR treatment, regardless of the mutational status of the KRAS and NRAS genes44. It should be noted that the application of deep learning (DL), a subfield of artificial intelligence (AI), comprises a potential tool to assist in the management of CCR45. Incorporation of this technology into histopathological classification, endoscopic tumor identification, imaging exams and laboratory tests associated with the diagnosis of CRC have been described46. An interesting application of DL, and most connected to our study, is the ability to predict the KRAS genotype directly from images of histopathological slides47. The limitations of this study include the sequencing technique used (Sanger sequencing), and the sample number which requires additional studies, with a larger sample number including different ethnic populations. Conclusions The rs121913529 was associated with alcoholism in individuals with CRC. Furthermore, the presence of somatic changes in TP53 has been shown to increase the chance of death in patients with CRC. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2